Abstract
Background: Despite advancements in Kasai portoenterostomy (KP) for biliary atresia (BA), 70-80% of patients require liver transplants with long waiting periods time. This study aims to investigate factors associated with mortality in BA patients awaiting liver transplantation. Methods: This cross-sectional study included BA patients indicated for liver transplantation from May 1, 2023 to August 30, 2024. Factors associated with the survival outcome were explored using univariable and multivariable logistic regression. The effect of the KP on overall survival was assessed through Kaplan-Meier survival analysis and multivariable Cox regression. Results: This study included 97 patients with a mortality rate of 16.5%. Multivariable logistic regression showed that KP (adjusted OR (aOR): 0.119; 95% CI: 0.021-0.678; P-value: 0.016), low pediatric end-stage liver disease (PELD) scores (aOR: 1.201; 95% CI: 1.074-1.343; P-value: 0.001), and high weight-for-age (WA) percentiles (aOR: 0.940; 95% CI: 0.884-0.999; P-value: 0.047) were associated with lower mortality. Sub-group analyses in patients with KP also showed low PELD scores (aOR: 1.155; 95% CI: 1.020-1.309; P-value: 0.023) related to lower mortality, whereas high GGT levels showed a potential association with survival (OR: 0.990; 95%CI: 0.981-1.000; P-value: 0.039). Further survival analysis demonstrated the prognostic value of KP (adjusted hazard ratio: 0.261; 95% CI: 0.088-0.770; P-value: 0.015). Conclusion: KP status and PELD scores are significantly associated with mortality risk in BA patients waiting for liver transplants, suggesting their potential role as early indicators for liver transplant prioritization. These findings are significant for informing follow-up care and early intervention strategies, though additional validation is necessary.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The observational study had a protocol approved by the Institutional Review Board of the Children's Hospital 2, Ho Chi Minh, Vietnam (No. 957/QĐ-NĐ2)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data supporting this study's findings are available upon reasonable request.
